Appl. No. 09/585,817
Amdt. dated June 4, 2003
Reply to Office Action of December 4, 2002

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-10: (Withdrawn)

Claim 11. (Currently Amended) A method of preventing or treating a prion disorder ~~characterized by amyloid deposition~~ in a mammalian subject, comprising administering to the subject a dosage of an agent effective to produce an immune response comprising antibodies against an amyloid component derived from a prion precursor protein (PrP) including genetic variants of the PrP associated with hereditary amyloidosis ~~characteristic of said disorder~~ and an adjuvant that augments the immune response to the amyloid component, and thereby preventing or treating the disorder.

Claims 12-13: (Canceled)

Claim 14. (Original) The method of claim ~~13~~ 11, wherein said agent induces an immune response directed against a neoepitope formed by said amyloid component with respect to said precursor protein.

Claim 15. (Currently Amended) The method of claim ~~13~~ 11, wherein said amyloid component is ~~selected from the group consisting of AA, AL, ATTR, AapoA1, Alys, Agel, Acys, Aβ, AB_2M, ASer,~~ AScr ~~PrP D178N, Aeal, AIAPP and synuclein NAC fragment~~.

Claim 16. (Currently Amended) The method of claim 15, wherein said agent is ~~selected from the group consisting of AA, AL, ATTR, AapoA1, Agel, Acys, Aβ, AB_2M,~~ AScr ~~, Aeal, AIAPP and synuclein NAC fragment~~ or PrP.

Claims 17-18: (Canceled)

Claim 19. (Original) The method of claim 11, wherein said agent is a peptide linked to a carrier moleculeprotein.

Claim 20. (Canceled)

Claim 21. (Currently Amended) The method of claim ~~20~~11, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum ~~and Freund's adjuvant~~.

Claim 22. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to said amyloid component.

Claim 23. (Currently Amended) The method of claim 22, wherein said serum titer of the antibodies is at least 1:5000 with respect to said ~~fibril~~ amyloid component.

Claim 24. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum ~~amount~~ titer of ~~immunoreactivity~~ the antibodies against the amyloid component corresponding to greater than about four times higher than a serum ~~level~~ titer of ~~immunoreactivity~~ antibodies measured in a pre-treatment control serum sample.

Claim 25. (Currently Amended) The method of claim 24, wherein said serum ~~amount~~ titer of ~~immunoreactivity~~ the antibodies is measured at a serum dilution of about 1:100.

Claims 26-57: (Canceled)